Luis E Echeverría1, Lyda Z Rojas2, Lauren S Calvo3, Zayne M Roa4, Oscar L Rueda-Ochoa5, Carlos A Morillo6, Taulant Muka7, Oscar H Franco8. 1. Heart Failure and Heart Transplant Clinic, Fundación Cardiovascular de Colombia, Floridablanca, Colombia. Electronic address: luisecheverria@fcv.org. 2. Department of Paediatrics, Obstetrics, Gynaecology and Preventative, Universidad Autónoma de Barcelona, Barcelona, Spain; Department of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands; Research Center Fundación Cardiovascular de Colombia, Floridablanca, Colombia. Electronic address: l.rojassanchez@erasmusmc.nl. 3. Research Center Fundación Cardiovascular de Colombia, Floridablanca, Colombia. Electronic address: laurencalvo@fcv.org. 4. Research Center Fundación Cardiovascular de Colombia, Floridablanca, Colombia. Electronic address: zayneroa@fcv.org. 5. Department of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands; Electrocardiography Research Group, Medicine School, Universidad Industrial de Santander, Bucaramanga, Colombia. Electronic address: o.ruedaochoa@erasmusmc.nl. 6. Department of Medicine, Cardiology Division, McMaster University, PHRI-HHSC, Hamilton, Ontario, Canada. Electronic address: morillo@hhsc.ca. 7. Department of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands. Electronic address: t.muka@erasmusmc.nl. 8. Department of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands. Electronic address: o.franco@erasmusmc.nl.
Abstract
BACKGROUND/ OBJECTIVES: Up 30 to 40% of Chagas patients exhibit cardiomyopathy with different degrees of cardiac involvement. Biomarkers may help in differentiation of the severity of Chagas cardiomyopathy (CCM). This study sought to examine the diagnostic value of a panel of biomarkers to distinguish the severity of (CCM). METHODS: 100 patients with CCM were included in this cross-sectional study. Based on electrocardiogram and echocardiogram, CCM patients were classified in three stages according to disease's severity. Levels of high-sensitivity cardiac troponin T (Hs-cTnT), N-terminal pro B-type natriuretic peptide (NT-proBNP), galectin-3 (Gal-3), neutrophil gelatinase-associated lipocalin (NGAL), soluble ST2 (sST2) and cystatin-c (Cys-c) were measured. Logistic regression models were used to assess the association between levels of natural log-transformed values of biomarkers and stages C/D versus B. We also calculated the area under curve (AUC) for each of the models. RESULTS: In models adjusted for age, sex, body mass index, kidney function and medication use, increased levels of NT-proBNP (per 1 unit natural log-transformed values, odds ratio (OR)=5.55; 95CI%:1.65-18.72) and Hs-cTnT (per 1 unit natural log-transformed values, OR=7.11; 95CI%:1.41-35.90) showed significant association with the severity of CCM per 1 unit increase of biomarkers. The accuracy of NT-proBNP and Hs-cTnT for diagnosis of the severity of CCM was high: AUC of 0.968 and 0.956 respectively. No significant difference was found in the AUC between NT-proBNP and Hs-cTnT. No association was found between Gal-3, NGAL, sST2 and Cys-C and severity of CCM. CONCLUSIONS: NT-proBNP and Hs-cTnT have both same diagnostic value in distinguishing severity of CCM.
BACKGROUND/ OBJECTIVES: Up 30 to 40% of Chagas patients exhibit cardiomyopathy with different degrees of cardiac involvement. Biomarkers may help in differentiation of the severity of Chagas cardiomyopathy (CCM). This study sought to examine the diagnostic value of a panel of biomarkers to distinguish the severity of (CCM). METHODS: 100 patients with CCM were included in this cross-sectional study. Based on electrocardiogram and echocardiogram, CCM patients were classified in three stages according to disease's severity. Levels of high-sensitivity cardiac troponin T (Hs-cTnT), N-terminal pro B-type natriuretic peptide (NT-proBNP), galectin-3 (Gal-3), neutrophil gelatinase-associated lipocalin (NGAL), soluble ST2 (sST2) and cystatin-c (Cys-c) were measured. Logistic regression models were used to assess the association between levels of natural log-transformed values of biomarkers and stages C/D versus B. We also calculated the area under curve (AUC) for each of the models. RESULTS: In models adjusted for age, sex, body mass index, kidney function and medication use, increased levels of NT-proBNP (per 1 unit natural log-transformed values, odds ratio (OR)=5.55; 95CI%:1.65-18.72) and Hs-cTnT (per 1 unit natural log-transformed values, OR=7.11; 95CI%:1.41-35.90) showed significant association with the severity of CCM per 1 unit increase of biomarkers. The accuracy of NT-proBNP and Hs-cTnT for diagnosis of the severity of CCM was high: AUC of 0.968 and 0.956 respectively. No significant difference was found in the AUC between NT-proBNP and Hs-cTnT. No association was found between Gal-3, NGAL, sST2 and Cys-C and severity of CCM. CONCLUSIONS: NT-proBNP and Hs-cTnT have both same diagnostic value in distinguishing severity of CCM.
Authors: Luis E Echeverría; Sergio Alejandro Gómez-Ochoa; Lyda Z Rojas; Karen Andrea García-Rueda; Pedro López-Aldana; Taulant Muka; Carlos A Morillo Journal: Front Cardiovasc Med Date: 2021-11-29
Authors: Ana Thereza Chaves; Ana Laura Grossi de Oliveira; Nathalia Sernizon Guimarães; Isabela Cristina Magalhães; Cristiane Alves da Silva Menezes; Manoel Otávio da Costa Rocha Journal: Rev Inst Med Trop Sao Paulo Date: 2022-06-24 Impact factor: 2.169
Authors: Lyda Z Rojas; Marija Glisic; Laura Pletsch-Borba; Luis E Echeverría; Wichor M Bramer; Arjola Bano; Najada Stringa; Asija Zaciragic; Bledar Kraja; Eralda Asllanaj; Rajiv Chowdhury; Carlos A Morillo; Oscar L Rueda-Ochoa; Oscar H Franco; Taulant Muka Journal: PLoS Negl Trop Dis Date: 2018-06-13
Authors: Luis Eduardo Echeverría; Rachel Marcus; Gabriel Novick; Sergio Sosa-Estani; Kate Ralston; Ezequiel Jose Zaidel; Colin Forsyth; Antonio Luiz P RIbeiro; Iván Mendoza; Mariano Luis Falconi; Jorge Mitelman; Carlos A Morillo; Ana Cristina Pereiro; María Jesús Pinazo; Roberto Salvatella; Felipe Martinez; Pablo Perel; Álvaro Sosa Liprandi; Daniel José Piñeiro; Gustavo Restrepo Molina Journal: Glob Heart Date: 2020-03-30
Authors: Kristyn A Hoffman; Corey Reynolds; Maria Elena Bottazzi; Peter Hotez; Kathryn Jones Journal: J Am Heart Assoc Date: 2019-11-13 Impact factor: 5.501